000161759 001__ 161759
000161759 005__ 20251017144558.0
000161759 0247_ $$2doi$$a10.1038/s41433-025-03871-6
000161759 0248_ $$2sideral$$a144381
000161759 037__ $$aART-2025-144381
000161759 041__ $$aeng
000161759 100__ $$aZarranz-Ventura, Javier
000161759 245__ $$aBrolucizumab clinical and safety outcomes in a neovascular age-related macular degeneration national database: Fight Retinal Blindness Spain (FRB Spain)
000161759 260__ $$c2025
000161759 5203_ $$aAim
To evaluate clinical outcomes, treatment intervals, and safety outcomes of brolucizumab (BRO) treatment in a national neovascular age-related macular degeneration (nAMD) database.
Methods
Multicentre, national, routine clinical care database study of nAMD eyes receiving ≥1 BRO injection. Demographics, visual acuity (VA) measured in logMAR letters, macular neovascularization (MNV) activity, number of injections, visit data and information on any adverse events were collected at baseline and at 3, 6, 9 and 12 months after BRO initiation for each patient/eye.
Results
A total of 305 eyes received
1 BRO injection and 214 eyes (14% naïve, 86% switchers) completed
3 months follow-up. In switchers, the percentage of eyes extended to ≥8 week intervals at 3/6/9 months was 43.2%/45.7%/54.5% and to ≥10 week intervals was 12.9%/18.5%/13.6%, respectively. Eyes with VA ≥ 70 increased from 36% at baseline to 48% at 3 months and 50% at 9 months. MNV lesion activity status decreased from 94% (active/active-only SRF, 46/48%) at baseline to 56% (21/35%), 61% (23/38%), 76% (27/49%) and 65% (24/41%) at months 3/6/9 and 12, respectively. Adverse effects were observed in 6.5% of the treated eyes, being the most prevalent anterior uveitis (3.2%), vitritis (4.5%) and vasculitis (2.2%).
Conclusion
In this series BRO achieves an extension in the treatment intervals in half of the patients which require frequent reinjections (<8 weekly), reducing MNV activity in a third of this specific difficult-to-treat subgroup. The adverse event rates described are consistent with other cohorts and need to be considered to inform treatment decisions in case-by-case discussions.
000161759 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000161759 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000161759 700__ $$aMarías-Pérez, Sonia
000161759 700__ $$aMartin-Pinardel, Ruben
000161759 700__ $$aFernandez-Bonet, Manel
000161759 700__ $$aPina-Marin, Begoña
000161759 700__ $$aCobos, Estefanía
000161759 700__ $$aRodríguez-Fernandez, Carmen Antía
000161759 700__ $$aParrado-Carrillo, Alba
000161759 700__ $$aAlarcón-Valero, Isaac
000161759 700__ $$aBarnes, Carles
000161759 700__ $$aCilveti, Esther
000161759 700__ $$aAramburu-Claveria, Julia
000161759 700__ $$0(orcid)0000-0001-9876-5850$$aAscaso-Puyuelo, Francisco J.$$uUniversidad de Zaragoza
000161759 700__ $$aFight Retinal Blindness Spain (FRB Spain)
000161759 7102_ $$11013$$2646$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Oftalmología
000161759 773__ $$pEye$$tEye (Basingstoke)$$x0950-222X
000161759 8564_ $$s3469199$$uhttps://zaguan.unizar.es/record/161759/files/texto_completo.pdf$$yVersión publicada
000161759 8564_ $$s2820287$$uhttps://zaguan.unizar.es/record/161759/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000161759 909CO $$ooai:zaguan.unizar.es:161759$$particulos$$pdriver
000161759 951__ $$a2025-10-17-14:13:46
000161759 980__ $$aARTICLE